Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Pediatr Allergy Immunol. 2018 Nov 20;30(1):117–122. doi: 10.1111/pai.12995

Table 2. Numbers of subjects with allergic outcomes across the 25(OH)D groups.

25(OH)D sufficiency
(≥ 75nmol/l)		 25(OH)D insufficiency
(≥50 nmol/l and <75 nmol/l)		 25(OH)D deficiency
(<50 nmol/l)
Outcomes by month 18 N(%) N(%) N(%)
Allergen sensitization 59 (13.5) 24 (12.5) 16 (17.6)
Eczema 103 (21.1) 37 (17.5) 19 (19.4)
Rhinitis 72 (18.0) 36 (21.8) 14 (21.2)
Wheeze and use nebulizer 56 (14.3) 26 (15.9) 11 (15.5)
Outcomes by month 36
Allergen sensitization 110 (25.1) 36 (18.4) 24 (17.0)
Eczema 119 (26.6) 47 (24.2) 23 (27.4)
Rhinitis 157 (40.7) 68 (43.6) 33 (50.8)
Wheeze and use nebulizer 91 (24.7) 34 (22.4) 13 (21.7)
Outcomes by month 60
Allergen sensitization 157 (38.2) 55 (31.4) 24 (30.0)
Eczema 126 (27.6) 48 (24.9) 25 (30.1)
Rhinitis 154 (41.6) 66 (44.3) 27 (46.6)
Wheeze and use nebulizer 108 (29.3) 46 (30.3) 20 (31.2)